(Name, dates, Thesis title, current or last known appointment)
- Greg O. Shearer (Ph.D., 1975), "A Mechanistic Study of Epoxidation by Cytochrome P-450 and Chemical Models."
- William H. Soine (Ph.D., 1978), "The Metabolism of Ferrocene and the Biological Activity of D,L-beta-Ferrocenyl-alpha-alanine." Professor of Medicinal Chemist (retired), Medical College of Virginia.
- John S. Walsh (M.S., 1979) "Studies on the Inhibition of Epoxide Hydrase." GlaxoSmithKline
- Kamlesh P. Vyas (co-directed Ph.D., 1979) Metabolism and Hepatotoxicity of Thiocarbonyl Compounds. Part I. Mechanism of Thiobenzamide-Induced Hepatotoxicity. Part II. Mechanism of alpha-Naphthylisothiocyanate-induced Hepatotoxocity. Merck Research Labs
- Richard B. Westkaemper (Ph.D., 1980), "Mechanistic Studies of Epoxide Hydrase and Related Model Reactions." Professor of Medicinal Chemistry, Medical College of Virginia
- John R. Cashman (Ph.D., 1982), "Toxicity, Metabolism and Chemistry of Thiobenzamide and Derivatives." President and CEO, Human BioMolecular Research Institute, San Diego, CA
- Stewart A. Thompson (Ph.D., 1983), "The Design, Synthesis and Evaluation of Peptide-Based Protease Inhibitors." Nektar Therapeutics.
- Robert H. Tullman (Ph.D., 1984), "Inactivation of Cytochromes P-450 and Monoamine Oxidase by Cyclopropylamines. Evidence for Cation-Radical Intermediates." Novartis Pharmaceuticals
- David A. Penney (co-directed Ph.D., 1984), "Part I. The Role of Metabolism in N-Methylthiobenzamide-Induced Pneumotoxocity. Part II. The Role of the Sympathetic Nervous System in Methylcyclopentadienyl Manganese Tricarbonyl-Induced Pneumotoxicity."
- Stephen P. Jacober (M.S., 1985), "Transition State Structures for the Enzymic Hydration of S- and R-p-Nitrostyrene Oxide." Boehringer-Ingelheim Pharmaceuticals
- K.-H. John Ling (M.S., 1987), "Kinetic Deuterium Isotope Effect on Phase-Transfer Catalyzed (PTC) Chlorination and Microsomal Hydroxylation of Xylenes." Allergan Corp.
- Larry R. Hall (Ph.D., 1989), "N-Dealkylation of Terriary Amides by Cytochrome P-450 and Anodic Oxidation." Bayer Animal Health
- Nicholas Andrew (M.S., 1990), "Secondary Deuterium Isotope Effects on Cytochrome P-450 Catalyzed Epoxidations." Merck Research Labs
- Siming Liu, (Ph.D. 1991), "Design, Synthesis and Mechanistic Application of New Cysteine Proteinase Inhibitors."
- Jiang Zheng (Ph.D. 1992), "The Isolation and Identification of New Premercapturic and Mercapturic Acid Metabolites of Bromobenzene." Assoc. Prof, University of Washington School of Medicine.
- Pamela Riley, (Ph.D., 1993), "Arylcyclopropanes as Mechanistic Probes of Cytochrome P450-Catalyzed Benzylic Oxidations." Proctor & Gamble, Inc.
- Hao Chen, (M.S., 1994), "Oxidation of Anilines and Anisoles with Cytochrome P450, Horseradish Peroxidase, Manganic Acetate and Ceric Bisulfate." Pfizer Pharmaceuticals
- Shawn Harriman, 1991-96 (Ph.D. 5/96) "The Formation and Fate of Reactive Metabolic Intermediates." Novartis Pharmaceuticals
- Ping Lu, 1992-96 (M.S. 12/95) "Active Site Mapping of Cytochrome P4504A1 by means of Substrate-Based Inhibitors." Merck Research Labs
- Christopher L. Shaffer, 1996-2001 (Ph.D., 2001) "Enzymatic N-dealkylation of a Cyclopropylamine. Fate of the Cyclopropyl Moiety and Its Mechanistic Implications." (This thesis won the Graduate School Dissertation Prize for 2001-2). Pfizer Pharmaceuticals
- Rheem A. Totah, 1997-2002 (PH.D., 2002) "Decarboxylation of Glycine Derivatives by a Peroxidase: A Mechanistic Study." Asst. Prof. of Medicinal Chemistry, University of Washington.
- Matthew A. Cerny, 1998-2005 (Ph.D., 2005) "Microsomal Metabolism of N-Benzyl-N-cyclopropylamine: Role of N-Oxidation in the Inactivation of Cytochromes P450." Arena Pharmaceuticals
For more information, please contact:
Dr. Robert P. Hanzlik
Department of Medicinal Chemistry
4048 Malott Hall
Tel: 785-864-3750
E-mail:
rhanzlik@ku.edu
